Zimmer Biomet (NYSE:ZBH) said today that it paid an unspecified amount to acquire CD Diagnostics and its line of immunoassay and biomarker products. Four years ago, the duo inked a pact that led to the development and marketing of the Synovasure periprosthetic joint infection test, Warsaw, Ind.-based Zimmer Biomet said. “I formed CD Diagnostics to solve the frustrating problem […]